Literature DB >> 27120316

Impact of Liver and Whole-Body Diffusion-Weighted MRI for Neuroendocrine Tumors on Patient Management: A Pilot Study.

Frederick Moryoussef1, Louis de Mestier, Mohamed Belkebir, Sophie Deguelte-Lardière, Hedia Brixi, Reza Kianmanesh, Christine Hoeffel, Guillaume Cadiot.   

Abstract

BACKGROUND: Computed tomography scan is the current standard cross-sectional imaging modality for neuroendocrine tumor (NET) workup. Diffusion-weighted magnetic resonance imaging (DW-MRI) has proven to be more sensitive than standard sequences to diagnose liver metastases; whole-body DW-MRI may be more sensitive than whole-body MRI. Clinical implications have not yet been assessed. Thus, we evaluated radiological and clinical contributions of liver and whole-body DW-MRI to manage NETs.
METHODS: Twenty-five abnormal liver and 22 abnormal whole-body standard MRIs were first analyzed retrospectively. MR images were then reanalyzed after adding DW sequences. The standard of reference for metastasis confirmation was a combination of radiological follow-up and histological proof. Clinical impact was defined as MRI changes of liver invasion (unilobar to bilobar and/or <50 to >50% of liver) or therapeutic management changes made during a dedicated multidisciplinary meeting after whole-body MRI.
RESULTS: Thirty-two patients with mainly small intestine NETs (24/32) were studied. Adding DW to standard liver MRI yielded additional findings for 45% of the patients with 1.78 times more new lesions, mainly infracentimetric; it induced a management change for 18% of the patients. DW sequences added to whole-body MRI yielded additional findings for 71% of the patients, with 1.72 times more lesions, mainly infracentimetric, and induced a change in management for 19% of the patients.
CONCLUSION: Adding DW sequences to standard MRI revealed additional metastases and led to modifications of patient management. Prospective studies are needed to confirm these results.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 27120316     DOI: 10.1159/000446369

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  9 in total

Review 1.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

2.  68Ga-DOTATATE PET/CT compared to standard imaging in metastatic neuroendocrine tumors: a more sensitive test to detect liver metastasis?

Authors:  Terence Jackson; Muhammad Darwish; Edward Cho; Kei Nagatomo; Houssam Osman; D Rohan Jeyarajah
Journal:  Abdom Radiol (NY)       Date:  2021-03-04

Review 3.  Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Andrew Canakis; Linda S Lee
Journal:  World J Gastrointest Endosc       Date:  2022-05-16

4.  Prospective comparison of whole-body MRI with diffusion-weighted and conventional imaging for the follow-up of neuroendocrine tumors.

Authors:  Maximilien Minon; Clothilde Soriano; David Morland; Thomas Walter; Côme Lepage; Antoine Tabarin; Mathilde Deblock; Pascal Rousset; Coralie Barbe; Christine Hoeffel; Guillaume Cadiot
Journal:  Endocrine       Date:  2019-09-28       Impact factor: 3.633

Review 5.  Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities.

Authors:  Ali Pirasteh; Petra Lovrec; Lisa Bodei
Journal:  Rev Endocr Metab Disord       Date:  2021-03-30       Impact factor: 9.306

6.  Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group.

Authors:  Rachel P Riechelmann; Rui F Weschenfelder; Frederico P Costa; Aline Chaves Andrade; Alessandro Bersch Osvaldt; Ana Rosa P Quidute; Allan Dos Santos; Ana Amélia O Hoff; Brenda Gumz; Carlos Buchpiguel; Bruno S Vilhena Pereira; Delmar Muniz Lourenço Junior; Duilio Reis da Rocha Filho; Eduardo Antunes Fonseca; Eduardo Linhares Riello Mello; Fabio Ferrari Makdissi; Fabio Luiz Waechter; Francisco Cesar Carnevale; George B Coura-Filho; Gustavo Andrade de Paulo; Gustavo Colagiovanni Girotto; João Evangelista Bezerra Neto; João Glasberg; Jose Claudio Casali-da-Rocha; Juliana Florinda M Rego; Luciana Rodrigues de Meirelles; Ludhmila Hajjar; Marcos Menezes; Marcello D Bronstein; Marcelo Tatit Sapienza; Maria Candida Barisson Villares Fragoso; Maria Adelaide Albergaria Pereira; Milton Barros; Nora Manoukian Forones; Paulo Cezar Galvão do Amaral; Raphael Salles Scortegagna de Medeiros; Raphael L C Araujo; Regis Otaviano França Bezerra; Renata D'Alpino Peixoto; Samuel Aguiar; Ulysses Ribeiro; Tulio Pfiffer; Paulo M Hoff; Anelisa K Coutinho
Journal:  Ecancermedicalscience       Date:  2017-01-26

7.  Fortuitous discovery of an early neuroendocrine tumor during appendicular peritonitis.

Authors:  Abdelilah El Bakouri; Anas El Wassi; Yassine Eddaoudi; Mounir Bouali; Khalid El Hattabi; Fatimazahra Bensardi; Abdelaziz Fadil
Journal:  Ann Med Surg (Lond)       Date:  2022-09-22

8.  Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors.

Authors:  X Merino-Casabiel; J Aller; J Arbizu; R García-Figueiras; C González; E Grande; P Jiménez-Fonseca; M I Sevilla; J Capdevila
Journal:  Clin Transl Oncol       Date:  2018-05-15       Impact factor: 3.405

9.  The impact of 18F-FDOPA-PET/MRI image fusion in detecting liver metastasis in patients with neuroendocrine tumors of the gastrointestinal tract.

Authors:  O Barachini; R Bernt; S Mirzaei; C Pirich; K Hergan; S Zandieh
Journal:  BMC Med Imaging       Date:  2020-02-24       Impact factor: 1.930

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.